Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 13, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 14, 2026
CEOOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references tax withholding
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001683168-26-001039
Filed / recorded
Feb 14, 2026, 4:10 AM UTC
Added to OQRO
Oct 8, 2026, 2:06 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ACTUATE THERAPEUTICS, INC.
Issuer CIK
1652935
Ticker
ACTU
Reporting person
Daniel M Schmitt
Relationship
Director, Officer
Officer title
President, CEO and Director
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Feb 13, 2026
Transaction code
M
Shares / units
272,055
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
272,055
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents the issuance of 272,055 shares of common stock from the vesting and settlement of 272,055 RSUs, which number excludes the withholding of 121,874 shares by Issuer to satisfy federal and state withholding taxes due at settlement (see Note 1).
Each restricted stock unit represents a contingent right to receive one share of common stock.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
